1 hour ago
1
bodrumsurf
- Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE) due to its development of the CB1 inhibitor nimacimab for obesity.
- The firm has a $10 price target (~206% upside based on Thursday's close).
- Analyst Michael DiFiore believes that
English (US) ·